The 25 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 75.00, with a high estimate of 220.00 and a low estimate of 43.00. The median estimate represents a +65.13% increase from the last price of 45.42.
The current consensus among 29 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.06
Reporting Date Nov 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.